Bringing mobile technologies to everyday practice
Atrial fibrillation (AFib) is a silent killer. As the most common cardiac arrhythmia it affects around 10 million people in Europe alone and the AFib population is growing at an alarming rate. By 2050, it is expected that the global AFib-population of 46.1 million will double to at least 92 million. The lifetime risk of developing AFib is 25%, and this risk quickly increases with age.
AFib often leads to heart failure, kidney problems and coronary heart disease, and it is the cause of more than 20% of all strokes. AFib episodes can be accompanied by palpitations, fainting, shortness of breath, or chest pain, but often none of these symptoms are present and a stroke is the first symptom that presents itself.
FibriCheck is an innovative way to measure heart rhythm regularly and detect AFib using only a standard smartphone or smartwatch. Users can measure heart rhythm simply by placing their finger on the camera of their smartphone. This award-winning application, built around patented, highly accurate measuring and detection algorithms, is the first software-only, medically approved application able to detect AFib and other common arrhythmias in only 60 seconds.
The app has been commercially available in Europe since 2017. It is supported by the medical community, used by more than 30 000 people and reimbursed by selected health care funds. In October, the American Food & Drug Administration (FDA) approved FibriCheck as a medical smartphone application, opening the way to the US market. This is the first time the FDA approves a smartphone application designed to detect heart rhythm disorders without using any external medical devices. The company had opened an office in San Francisco earlier in the year in preparation.
Qompium, the SME behind FibriCheck, aims to bring certified digital health applications to everyday practice by offering user-friendly, high-quality and proven mobile applications at a low cost.
- October 2018: Winner of EIT Venture Award at INNOVEIT, including Europe-wide promotion and €50 000.
- May 2018: Winner of the Social Care Award at Arch Summit (organized by Vodaphone), resulting in Vodaphone contacts, collaboration and a €50 000 grant.
- December 2017: Winner of the Digital Health category of the EIT Health European Health Catapult contest, an award that comes with European healthcare market advice, access to the extensive, international EIT Health network and a €20 000 grant.
- November 2017: Winner of the FXH award of Roche, resulting in access to a German accelerator program, a pilot study with Roche and a €10 000 grant.
- August 2017: Most innovative digital health company award from the European Society of Cardiology, Barcelona.
- April 2017: Best mobile health app in Europe at ConHit, Berlin.
- March 2016: Audience prize at the Aging 2.0 conference in San Francisco.
- July 2015: eHealth award for best mobile health project (Agoria).
- August 2014: Bayer Healthcare for the Grants4Apps accelerator programme, which included coaching, office space and €50 000 of seed funding
Benefits of EIT Health support
Qompium has received extensive support from EIT Health in terms of funding and recognition:
- EIT Health Head Start Grant for €50 000 prepared FibriCheck for market entry.
- Support in the EIT Health Product/Market Fit programme (worth €25 000) allowed FibriCheck to exploit international markets.
- Winner of the Digital Health category of the EIT Health European Health Catapult contest, an award that comes with European healthcare market advice, access to the extensive, international EIT Health network and a €20 000 grant.
Furthermore, EIT Health also opened up their network to FibriCheck, an association that has resulted in interesting discussions and potential partnerships with large corporations and insurance companies. Access to potential investors was also facilitated through several EIT Health pitching events.
See a video: